CAR T-cell therapies: formulation-product-proposition framework for commercialisation

Drug Discov Today. 2016 Nov;21(11):1731-1734. doi: 10.1016/j.drudis.2016.09.008. Epub 2016 Sep 17.

Authors

Nafees N Malik¹, Matthew B Durdy²

Affiliations

¹ Asklepian Consulting, International House, 24 Holborn Viaduct, London EC1A 2BN, United Kingdom. Electronic address: nmalik@asklepianconsulting.com.
² Cell and Gene Therapy Catapult, 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom.

PMID: 27649941
DOI: 10.1016/j.drudis.2016.09.008

No abstract available

Publication types

Editorial

MeSH terms

Drug Compounding
Drug Industry / economics
Drug Industry / trends*
Humans
Immunotherapy, Adoptive / economics
Immunotherapy, Adoptive / trends*
Receptors, Antigen / chemistry
Receptors, Antigen / therapeutic use*
T-Lymphocytes*
Technology Transfer*

Substances

Receptors, Antigen